The Confusion Is Understandable

Both IBS (Irritable Bowel Syndrome) and IBD (Inflammatory Bowel Disease) affect the digestive tract. Both cause abdominal pain, altered bowel habits, and significant quality-of-life impairment. Both are common. And both are frequently misunderstood — even by healthcare providers.

But they are mechanistically distinct conditions that require entirely different approaches.

IBS: A Functional Disorder

IBS is classified as a functional gastrointestinal disorder — meaning that while symptoms are real and often debilitating, there is no structural damage or inflammation visible on endoscopy or imaging. The gut looks normal. The problem lies in how it functions.

IBS is characterised by:

  • Abnormal gut-brain signalling (visceral hypersensitivity — the gut overreacts to normal stimuli)
  • Altered gut motility (too fast, too slow, or erratic)
  • Microbiome dysbiosis in a significant subset of patients
  • Heightened immune activation in the gut lining without frank inflammation
IBS affects approximately 10–15% of the global population, making it one of the most common diagnoses in gastroenterology. It does NOT increase the risk of cancer or cause permanent bowel damage.

IBD: Structural Inflammation

IBD is a fundamentally different category — an autoimmune condition characterised by chronic, recurring inflammation that causes visible structural damage to the digestive tract. IBD encompasses two main conditions:

Crohn's Disease

Can affect any part of the GI tract from mouth to anus, but most commonly the terminal ileum (end of small intestine) and colon. Inflammation is transmural — it penetrates all layers of the bowel wall — and creates characteristic "skip lesions" (patches of inflammation separated by healthy tissue). Can lead to strictures, fistulas, and abscesses.

Ulcerative Colitis (UC)

Affects only the colon (large intestine) and rectum. Inflammation is confined to the mucosal layer (innermost). Progresses continuously from the rectum upward. Associated with increased colorectal cancer risk after 8–10 years of active disease.

Key Diagnostic Differences

The distinction is made through a combination of investigations:

  • Bloodwork — IBD typically shows elevated CRP, ESR, and faecal calprotectin; IBS does not
  • Colonoscopy with biopsy — the gold standard; IBD shows inflammation, ulceration, or structural changes; IBS appears normal
  • Imaging (MRI/CT) — used in Crohn's to assess small bowel involvement
  • Faecal calprotectin — a non-invasive marker of gut inflammation; elevated in IBD, normal in IBS

Why This Distinction Matters

Treatment approaches differ dramatically:

  • IBS is managed through dietary modification (low-FODMAP, fibre adjustment), gut-directed psychotherapy, and targeted medications (antispasmodics, low-dose antidepressants for visceral hypersensitivity)
  • IBD requires immunosuppressive or biologic therapy (anti-TNF agents, JAK inhibitors) and regular endoscopic monitoring

Misdiagnosis in either direction is problematic. An IBS patient given immunosuppressants is exposed to unnecessary risks. An IBD patient given dietary advice alone may experience disease progression, complications, or colorectal cancer that could have been prevented.

If you're experiencing persistent gut symptoms, proper diagnosis by a gastroenterologist — including blood tests and imaging — is essential before starting any treatment protocol. Self-diagnosing IBS when IBD is the cause can have serious consequences.